1992
DOI: 10.1016/0378-3782(92)90164-c
|View full text |Cite
|
Sign up to set email alerts
|

A prospective, randomized trial of early versus late administration of a single dose of surfactant-TA

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
24
0

Year Published

1998
1998
2021
2021

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 41 publications
(24 citation statements)
references
References 6 publications
0
24
0
Order By: Relevance
“…C hronic lung disease (CLD) of prematurity has multifactorial etiologies including hyperoxia, 1 barotrauma, 2 surfactant deficiency, 3 nutritional deficiencies, 4,5 fluid overload, 6,7 patent ductus arteriosus (PDA), 8 inflammation of the lungs, 9 and infection. 10 -12 With respect to infection, several microorganisms have been implicated; Chlamydia trachomatis, cytomegalovirus, adenovirus, and Ureaplasma urealyticum.…”
mentioning
confidence: 99%
“…C hronic lung disease (CLD) of prematurity has multifactorial etiologies including hyperoxia, 1 barotrauma, 2 surfactant deficiency, 3 nutritional deficiencies, 4,5 fluid overload, 6,7 patent ductus arteriosus (PDA), 8 inflammation of the lungs, 9 and infection. 10 -12 With respect to infection, several microorganisms have been implicated; Chlamydia trachomatis, cytomegalovirus, adenovirus, and Ureaplasma urealyticum.…”
mentioning
confidence: 99%
“…Several trials of rescue surfactant therapy have demonstrated the benefits of early surfactant treatment. [1][2][3] The reduction in median time to surfactant for all infants Ͻ37 weeks' gestation to 121 minutes represents a 53% reduction from the pretrial audit and a 44% reduction compared with controls. The benefits were almost exclusively seen for infants of Ͻ28 weeks' gestation who were nearly always intubated before admission.…”
Section: Infants <28 Weeks' Gestationmentioning
confidence: 99%
“…Although this trial was not of sufficient size to have the power to detect clinically important improvements in these respiratory outcomes, the literature adequately documents the benefits of early surfactant in these infants. [1][2][3] An alternative to targeted early rescue therapy using a bedside test of surfactant is to give all preterm infants at risk of RDS surfactant at birth (surfactant prophylaxis). The benefits of early surfactant are supported by the trials of prophylactic versus rescue surfactant in terms of reductions in short-term morbidity and mortality of preterm infants.…”
Section: Infants <28 Weeks' Gestationmentioning
confidence: 99%
See 1 more Smart Citation
“…Other studies favoring prophylactic surfactant have found improved survival, decreased morbidity, decreased dependence on oxygen at the expected date of delivery, and lower risk of pneumothorax. 3,9,10 However, some trials have found no significant advantage of PRx over RRx and recommend RRx because of unnecessary treatment of surfactant-sufficient neonates. 8,[11][12][13] Comparisons of the early neurodevelopmental outcomes of PRx versus RRx also have produced mixed results.…”
mentioning
confidence: 99%